Why People Are Disappointed with Astaxanthin

Scientific concepts, discoveries, and nature/biology phenomena

Astaxanthin as an antioxidant carotenoid

Astaxanthin is presented as a powerful antioxidant, with evidence discussed in areas including:

• Skin
• Eyes
• Inflammation
• Cholesterol

Longevity/lifespan testing in mice via the Interventions Testing Program (ITP)

Earlier (positive) ITP study (about 2 years prior)

• Dosing/timing: Astaxanthin started at 12 months of age
• Achieved dietary concentration: ~1,840 ppm (reported average), despite a headline reference to higher levels
• Outcome: ~12% longer median lifespan in male mice
• Sex effects: Effects were not robust across females, with only a partial/uncertain signal at one site

Newer (negative) ITP study

• Dosing: Lower dose, ~880 ppm
• Timing: Start age varied by group (started earlier or later depending on group)
• Outcome: No lifespan extension

Interpretation offered

• The differing results are attributed mainly to different protocols (dose and timing).
• Sex-specific and dose-specific effects are emphasized:
  • Lifespan benefit appeared primarily in males
  • Suggests a threshold dose may be required; below it, effects may disappear

Dose feasibility / translational relevance to humans

The mouse-achieved dietary exposures are argued to be far higher than realistic human intake.

Approximate dose conversion described for an 80 kg male:

• Positive mouse exposure
  • Estimated human-equivalent intake: ~1.8 g/day
  • Compared with common supplements (~12 mg/capsule): ~150 capsules/day
  • Described as not achievable via food
• Food feasibility via salmon astaxanthin content
  • Salmon astaxanthin given as ~0.4 to 3.8 mg per 100 g
  • Implies tens of kilograms per day would be required (infeasible)

Even the lower ITP dose (880 ppm) is argued to correspond to about:

• ~850 mg/day for an 80 kg adult
• ~71 capsules/day (at 12 mg each) Still described as above typical use.

Why the supplement may still be worthwhile: human trial evidence (non-lifespan outcomes)

Skin protection / UV-related oxidative stress mitigation

A 2021 systematic review & meta-analysis of RCTs reported:

• Oral astaxanthin: 2–12 mg/day for 4–16 weeks
• Reported improvements:
  • Moisturization: ~10–15%
  • Elasticity: ~3–10%

Eye protection against screen-related oxidative stress

A 2025 RCT in children aged 10–14 years reported:

• Dose: 4 mg/day for 84 days
• Outcomes: reduced digital eye strain and improved visual fatigue

Inflammation biomarker improvement (hs-CRP)

A 2020 meta-analysis of clinical trials reported:

• >12 mg/day for >12 weeks: reduced hs-CRP ~19–26%
• Lower doses (<12 mg) or shorter duration (<12 weeks): no effect (as described)

Cholesterol effects

Two meta-analyses are cited:

• 2020 meta-analysis:
  • 12 mg/day most consistently increased HDL ~3%
• 2022 meta-analysis:
  • ~3.5% decrease in LDL with 4–20 mg/day

---

Methods or lists mentioned (protocol comparison)

Key methodological drivers emphasized for ITP lifespan studies

• Dose level (achieved dietary concentration)
  • Positive study: ~1,840 ppm
  • Negative study: ~880 ppm
• Start age / timing
  • Positive study: started at 12 months
  • Negative study: start age varied by group (earlier or later)
• Sex-specific analysis
  • Male mice showed lifespan benefit in the positive study
  • Female results were inconsistent across sites

---

Researchers or sources featured (as named in the subtitles)

• Interventions Testing Program (ITP) (no individual researchers named)
• 2021 systematic review & meta-analysis of randomized controlled trials (no authors named)
• 2025 randomized controlled trial in children aged 10–14 (no authors named)
• 2020 meta-analysis of clinical trials for hs-CRP/HDL (no authors named)
• 2022 meta-analysis of clinical trials for LDL (no authors named)